GlaxoSmithKline plc (GSK,GSK.L) and Theravance Inc. (THRX) announced the FDA acceptance of the New Drug Application or NDA for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" or FF/VI for patients with chronic obstructive pulmonary disease or COPD, thereby indicating that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act or PDUFA goal date has also been confirmed as May 12, 2013.
On July 13, 2012, GSK and Theravance reported the submission by GSK of regulatory applications in the U.S. and European Union for FF/VI for patients with COPD and a regulatory application for asthma in the European Union. The Marketing Authorisation Application or MAA for FF/VI for COPD and asthma has been validated by the European Medicines Agency or EMA.
In addition, GSK submitted a Japanese New Drug Application for FF/VI for patients with COPD and asthma on September 25, 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.